ArticleFrontiers in digital health2026
Beyond accuracy: evaluating the operational feasibility and diagnostic yield of CAD4TB vs. Timika score for scalable TB screening in low-resource settings.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence has shown promise in enhancing tuberculosis care, but its use in resource-limited settings like Indonesia remains underexplored. This cross-sectional retrospective single-centre study evaluates the diagnostic performance of CAD4TB in screening Indonesian patients suspected of tuberculosis using chest x-ray (CXR) images, comparing its efficacy to the Timika score assessed by experts. We analyzed CXR images from 3,254 patients (2018-2020), including 600 with microbiological confirmation, of whom 46 had smear-positive pulmonary tuberculosis (PTB). CAD4TB demonstrated an area under the curve (AUC) of 0.778 (95% CI 0.712-0.844) when compared to acid-fast bacilli (AFB) results without a time interval. With a ≤7-day interval between CXR and AFB data, CAD4TB showed an AUC of 0.767 (95% CI 0.668-0.866), comparable to the Timika score of 0.726 (95% CI 0.632-0.820). Additionally, CAD4TB exhibited superior specificity (71.43% vs. 57.64%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.